Role of Endocannabinoids on Neuroinflammation in Autism Spectrum Disorder Prevention
Published: June 1, 2017 | DOI: https://doi.org/10.7860/JCDR/2017/23862.9969
Syed Shahid Habib, Khalid Al-Regaiey, Shahid Bashir, Muhammad Iqbal
1. Professor, Department of Physiology, King Saud University, Riyadh, Saudi Arabia.
2. Assistant Professor, Department of Physiology, King Saud University, Riyadh, Saudi Arabia.
3. Assistant Professor, Department of Physiology, King Saud University, Riyadh, Saudi Arabia.
4. Researcher, Department of Physiology, King Saud University, Riyadh, Saudi Arabia.
Correspondence
Dr. Syed Shahid Habib,
Professor, Department of Physiology, King Saud University, Riyadh, Saudi Arabia.
E-mail: shahidhabib44@hotmail.com
Autism Spectrum Disorder (ASD) disease has become a mounting socio-economical alarm around the world. Neuroinflammtion had been shown in postmortem brain specimens from ASD patients. The Endocannabinoids System (ES) consists of a family of locally produced, short-lived, endogenous, phospholipid-derived agonists (endocannabinoids) that control energy balance and body composition. The growing number of medical benefits of ES, such as their ability to regulate processes like neuroinflammation, neurogenesis and memory, raise the question of their potential role as a preventive treatment of ASD.
To test this hypothesis, basic and clinical studies allow us a thorough investigation of the role of ES in the pathogenesis of ASD. This hypothesis will help to understand the mechanism of ES and its role in ASD.
[
FULL TEXT ] | [ PDF]